Coronavirus Live Count Map India
remove_red_eye 1349 Views
Coronavirus Live Count Map World
#Internal Medicine #Pharmacist #Pulmonary Medicine
Coronavirus FAQ PDF
Inhaled triple therapy with budesonide, glycopyrrolate, and formoterol showed a signal of reducing all-cause mortality in patients with moderate to severe chronic obstructive pulmonary disease (COPD) at higher (320 μg) budesonide doses, suggest new findings from the large, multicenter, 52-week ETHOS trial.
Two doses of the glucocorticoid -- 160 μg and 320 μg -- were evaluated in the trial. The trial compared twice-daily doses of the triple therapy with dual treatment with glycopyrrolate and formoterol or formoterol and budesonide. Presenting the findings at an American Thoracic Society 2020 virtual session, Klaus Rabe, MD, of the Airway Research Center North in Grosshansdorf, Germany, revealed that at both budesonide doses, twice-daily treatment with the single inhaler triple therapy was associated with significantly lower rates of moderate to severe COPD exacerbations, compared with the dual treatments… (Medpage Today)